Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study
Abstract Background Brentuximab vedotin (BV) was approved as a therapy for patients with CD30‐positive lymphoma in China in 2020 based on the results of multiple clinical trails. Few Chinese real‐world data of its use are yet available. Herein, we present the application situation of BV in patients...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-12-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.6733 |
| _version_ | 1797371915908677632 |
|---|---|
| author | Xudong Zhang Honghan Qiao Xiaofei Chai Xue Gao Rongjun Ma Yufu Li Zunmin Zhu Mingzhi Zhang |
| author_facet | Xudong Zhang Honghan Qiao Xiaofei Chai Xue Gao Rongjun Ma Yufu Li Zunmin Zhu Mingzhi Zhang |
| author_sort | Xudong Zhang |
| collection | DOAJ |
| description | Abstract Background Brentuximab vedotin (BV) was approved as a therapy for patients with CD30‐positive lymphoma in China in 2020 based on the results of multiple clinical trails. Few Chinese real‐world data of its use are yet available. Herein, we present the application situation of BV in patients with lymphoma among different hospitals in Henan province in China under real‐world conditions. Methods This was a multicenter and retrospective study in 104 patients with lymphoma who received BV for the first time between August 2020 and September 2022 across eight centers in Henan province. Data on the clinical use, effectiveness and adverse events (AEs) of BV were extracted from patient medical records. Short‐term effectiveness was assessed based on objective response rate (ORR), complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). Progression‐free survival (PFS) and overall survival (OS) were calculated using Kaplan–Meier method. Safety was also evaluated in our study. Results 104 lymphoma patients were enrolled in our study, who had completed a median of two cycles (range,1–8) of BV‐based treatment. A total of 72.1% of patients were relapsed/refractory (R/R) lymphoma, and only 27.9% were previously untreated lymphoma who received BV in frontline treatment settings. Among them who received effectiveness evaluation, the ORR achieved 64.5% (CR 25.8%, PR 38.7%). After a median follow‐up of 11 months, the 6‐month PFS rate and OS rate achieved 77.2% and 90.1% respectively, and the 12‐month PFS rate and OS rate achieved 77.2% and 79.9% respectively. In general, BV‐based treatment was well‐tolerated, with 38.5% incidence of grade ≥3 AEs. The most commonly reported AEs were hematologic disorders, especially neutropenia, with the incidence reaching 50.0%. Conclusions BV‐based regimens could be a promising therapeutic option with remarkable effectiveness and moderate toxicity in treating Chinese lymphoma patients with CD30 expression. |
| first_indexed | 2024-03-08T18:28:49Z |
| format | Article |
| id | doaj.art-7d9f510c347342b099bdef5852e78468 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-03-08T18:28:49Z |
| publishDate | 2023-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-7d9f510c347342b099bdef5852e784682023-12-30T08:53:25ZengWileyCancer Medicine2045-76342023-12-011224217252173410.1002/cam4.6733Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world studyXudong Zhang0Honghan Qiao1Xiaofei Chai2Xue Gao3Rongjun Ma4Yufu Li5Zunmin Zhu6Mingzhi Zhang7The First Affiliated Hospital of Zhengzhou University ZhengZhou ChinaThe First Affiliated Hospital of Zhengzhou University ZhengZhou ChinaThe First Affiliated Hospital of Zhengzhou University ZhengZhou ChinaHenan Cancer Hospital ZhengZhou ChinaHenan Provincial People's Hospital ZhengZhou ChinaHenan Cancer Hospital ZhengZhou ChinaHenan Provincial People's Hospital ZhengZhou ChinaThe First Affiliated Hospital of Zhengzhou University ZhengZhou ChinaAbstract Background Brentuximab vedotin (BV) was approved as a therapy for patients with CD30‐positive lymphoma in China in 2020 based on the results of multiple clinical trails. Few Chinese real‐world data of its use are yet available. Herein, we present the application situation of BV in patients with lymphoma among different hospitals in Henan province in China under real‐world conditions. Methods This was a multicenter and retrospective study in 104 patients with lymphoma who received BV for the first time between August 2020 and September 2022 across eight centers in Henan province. Data on the clinical use, effectiveness and adverse events (AEs) of BV were extracted from patient medical records. Short‐term effectiveness was assessed based on objective response rate (ORR), complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). Progression‐free survival (PFS) and overall survival (OS) were calculated using Kaplan–Meier method. Safety was also evaluated in our study. Results 104 lymphoma patients were enrolled in our study, who had completed a median of two cycles (range,1–8) of BV‐based treatment. A total of 72.1% of patients were relapsed/refractory (R/R) lymphoma, and only 27.9% were previously untreated lymphoma who received BV in frontline treatment settings. Among them who received effectiveness evaluation, the ORR achieved 64.5% (CR 25.8%, PR 38.7%). After a median follow‐up of 11 months, the 6‐month PFS rate and OS rate achieved 77.2% and 90.1% respectively, and the 12‐month PFS rate and OS rate achieved 77.2% and 79.9% respectively. In general, BV‐based treatment was well‐tolerated, with 38.5% incidence of grade ≥3 AEs. The most commonly reported AEs were hematologic disorders, especially neutropenia, with the incidence reaching 50.0%. Conclusions BV‐based regimens could be a promising therapeutic option with remarkable effectiveness and moderate toxicity in treating Chinese lymphoma patients with CD30 expression.https://doi.org/10.1002/cam4.6733brentuximab vedotineffectivenesslymphomareal‐world studysafety |
| spellingShingle | Xudong Zhang Honghan Qiao Xiaofei Chai Xue Gao Rongjun Ma Yufu Li Zunmin Zhu Mingzhi Zhang Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study Cancer Medicine brentuximab vedotin effectiveness lymphoma real‐world study safety |
| title | Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study |
| title_full | Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study |
| title_fullStr | Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study |
| title_full_unstemmed | Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study |
| title_short | Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study |
| title_sort | brentuximab vedotin in treating chinese patients with lymphoma a multicenter real world study |
| topic | brentuximab vedotin effectiveness lymphoma real‐world study safety |
| url | https://doi.org/10.1002/cam4.6733 |
| work_keys_str_mv | AT xudongzhang brentuximabvedotinintreatingchinesepatientswithlymphomaamulticenterrealworldstudy AT honghanqiao brentuximabvedotinintreatingchinesepatientswithlymphomaamulticenterrealworldstudy AT xiaofeichai brentuximabvedotinintreatingchinesepatientswithlymphomaamulticenterrealworldstudy AT xuegao brentuximabvedotinintreatingchinesepatientswithlymphomaamulticenterrealworldstudy AT rongjunma brentuximabvedotinintreatingchinesepatientswithlymphomaamulticenterrealworldstudy AT yufuli brentuximabvedotinintreatingchinesepatientswithlymphomaamulticenterrealworldstudy AT zunminzhu brentuximabvedotinintreatingchinesepatientswithlymphomaamulticenterrealworldstudy AT mingzhizhang brentuximabvedotinintreatingchinesepatientswithlymphomaamulticenterrealworldstudy |